Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRVB

Provention Bio (PRVB) Stock Price, News & Analysis

Provention Bio logo

About Provention Bio Stock (NASDAQ:PRVB)

Key Stats

Today's Range
$24.98
$25.00
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
9.12 million shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Macrogenics Inc MGNX
Nvidia’s world of pain awaits
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Sanofi completes Provention Bio acquisition
See More Headlines

PRVB Stock Analysis - Frequently Asked Questions

Provention Bio, Inc. (NASDAQ:PRVB) issued its earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.08. The business earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
11/04/2021
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%

Debt

Sales & Book Value

Annual Sales
$12.90 million
Book Value
$1.40 per share

Miscellaneous

Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:PRVB) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners